Physician profile
John Pennington
NPI 1063506921
$2,198.34
in general payments reported to CMS, 2019-2025
25 companies · $62.31 in 2025
The $62.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $339 · 2021: $418 · 2022: $424 · 2023: $561 · 2024: $35.92 · 2025: $62.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.06 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $301.33 | 2022-2023 | |
| Lilly USA, LLC | $237.03 | 2019-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $171.48 | 2020-2024 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $163.75 | 2019-2022 | |
| Amgen INC. | $79.12 | 2019-2022 | |
| Esperion Therapeutics, INC. | $64.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $59.67 | 2019-2021 | |
| Glaxosmithkline, LLC. | $52.60 | 2022-2023 | Trelegy Ellipta |
| Abbott Laboratories | $49.71 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Ironwood Pharmaceuticals, INC | $46.45 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.54 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.53 | 2022 | |
| Boston Scientific Corporation | $42.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.61 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.12 | 2020 | |
| Merck Sharp & Dohme LLC | $33.12 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $23.48 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $23.48 | 2022 | |
| Seqirus USA INC | $18.61 | 2025 | Flucelvax, Fluad |
| Shire North American Group INC | $18.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.68 | 2025 | Adstiladrin |
| Exact Sciences Corporation | $16.60 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $15.56 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.